Tolvaptan (Otsuka).
Otsuka is developing tolvaptan (OPC-41061), an orally active non-peptide vasopressin V2 antagonist, as a diuretic for the potential treatment of congestive heart failure. By November 2003, tolvaptan was undergoing phase III clinical trials.